GSK Announces Positive Phase III Data For RSV Vaccine Candidate For Older Adults
10/6 08:59
(RTTNews) - GSK plc. (GSK, GSK.L) announced a positive pivotal phase III data for its respiratory syncytial virus vaccine candidate for adults aged 60 years and above....